Clinical Trial

Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A total of 224 subjects of HER2-positive advanced breast cancer with brain metastases are planned to be enrolled. Eligible subjects will be randomly assigned in a 1:1 ratio to the group receiving Trastuzumab Rezetecan combined with radiotherapy or the group receiving Trastuzumab Rezetecan monotherapy until disease progression, intolerable toxicity, withdrawal of informed consent, or the study determines that treatment must be terminated (whichever occurs first).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-27.
Trial Details
NCT Number NCT07100600
Lead Sponsor Henan Cancer Hospital
Conditions HER2-positive Advanced Breast Cancer, Brain Metastases, Radiotherapy
Enrollment 224 participants
Start Date 2025-08-30
Primary Completion 2030-07-30 (estimated)
Study Completion 2032-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-11